Absorbable sutures -- or stitches -- are commonly used after surgery to help a patient's wound heal. These type of sutures are absorbed by the body and do not need to be removed. One type of suture, however, has caused more harm than good.
The Panacryl Suture
The Panacryl suture was marketed by Ethicon, Inc., a division of Johnson & Johnson, as being unique for its combined superior strength and absorbability. Ethicon stated that the suture was useful where extended wound support was needed for up to six months.
Panacryl sutures are braided synthetic absorbable sutures that were used in general soft tissue and orthopedic uses including tendon and ligament repairs and reattachment to bone.
Problems with Panacryl
Despite the optimistic claims of its maker, use of the Panacryl suture was associated with post-surgery complications. Some of the problems experienced include:
- Non-absorption by the body
- Suture granulomas
- Suture “spitting”
- Extremely high rate of infection
Some surgeons have described a “tunneling” effect where the suture inhibits healthy tissue growth. This results in the appearance of miniature mole tunnels at or about the incision site where the Panacryl sutures were used.
In most cases, additional surgeries were necessary to remove the infected sutures. Recovery times for infected patients varied from a few months to as long as one year. In some cases, the sutures remained inside the patient's body for one to two years before the granulomas and/or infections occurred.
Most of the problems with the Panacryl sutures were associated with its use in the lower abdominal area in what are commonly referred to as “soft tissue” areas.
The sutures were introduced to the market in 1999 and were removed from the market in July 2002.